Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    What do advanced cancer patients know of their disease? (1994)
    Springer
    Supportive care in cancer 2 (1994), S. 242-244 
    Details
    ISSN: 1433-7339
    Keywords: Cancer diagnosis ; Disclosure ; Informaed consent ; Quality of care ; Truth telling
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract The aim of this work was to investigate the awareness of diagnosis, prognosis and meaning of palliative treatment in Italian patients with advanced, incurable cancers. A group of 100 patients, referred to a Medical Oncology facility, were interviewed. Only 38 patients were aware of the malignant neoplastic nature of their disease. The remaining patients believed they had a benign neoplasia, non-neoplastic disease, or were unable to define their illness. No patient had a correct idea of the poor prognosis of the disease. Only 11.5% of 87 patients receiving chemotherapy had a correct perception of the palliative intent of the treatment, while most believed that the chemotherapy was “preventive”. Dissatisfaction with the information received was expressed by a minority of patients. The awareness of diagnosis was better among women and patients with a higher educational background. Witholding the truth from cancer patients still seems very common in Italy.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF00365729
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Tamoxifen and the endometrium: findings of pelvic ultrasound examination (1998)
    Springer
    Breast cancer research and treatment 47 (1998), S. 41-46 
    Details
    ISSN: 1573-7217
    Keywords: adjuvant therapy ; endometrial biopsy ; endometrial cancer ; tamoxifen ; ultrasonography
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract The need for endometrial surveillance in breast cancer patients undergoing adjuvant treatment with tamoxifen is still controversial. In this study, 164 asymptomatic breast cancer patients (110 on treatment with tamoxifen, 20 mg/day, and 54 controls) were examined with pelvic ultrasound and endometrial biopsy. No differences in ultrasound and biopsy findings were observed in the pre- and perimenopausal group between patients treated with tamoxifen and controls. Postmenopausal patients on tamoxifen had a significantly thicker endometrium (mean ± SD, 7.2 ± 8.5 vs. 1.5 ± 4.3 mm, p=0.00002) and significantly larger uterine volume (mean ± SD, 63.2 ± 39.9 vs. 43.7 ± 38.8 cm3, p=0.0001) than controls. Fifty-four percent of patients on tamoxifen had an endometrial thickness ≥ 5 mm, often with multiple irregular sonolucencies suggesting the presence of cysts. Ultrasound findings, however, did not correlate with the presence of endometrial abnormalities on biopsy, and no endometrial cancer or atypical hyperplasia were found. This lack of correlation makes questionable the use of routine sonography in asymptomatic breast cancer patients on tamoxifen. Obtaining routine endometrial samples, on the other hand, may be difficult in some patients because of cervical stenosis or refusal. Until the benefits of endometrial surveillance will be proved, asymptomatic patients should not be submitted routinely to ultrasound examination or biopsy, but encouraged to report promptly any abnormal vaginal bleeding.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1005820115535
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 3
    Electronic Resource
    Electronic Resource
    Cisplatin and 5-fluorouracil in refractory breast cancer patients: A phase II study (1988)
    Springer
    Breast cancer research and treatment 11 (1988), S. 269-271 
    Details
    ISSN: 1573-7217
    Keywords: breast cancer ; chemotherapy ; cisplatin/5-fluorouracil synergism ; salvage therapy
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary 24 patients with a median of 3 prior chemotherapy regimens were treated in our department with cisplatin 20 mg/m2 (with pre- and posthydration) and 5-fluorouracil 200 mg/m2 i.v. on day 1–5, every three weeks. 23 patients are evaluable; one had early death. 4 patients (17%) achieved a partial response, 8 had stable disease, and 11 progressed. Toxicity observed was moderate and no renal toxicity was noted. This study therefore shows tolerable toxicity but limited usefulness of adding cisplatin to 5-fluorouracil according to this schedule in these highly pretreated patients.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01807286
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 4
    Electronic Resource
    Electronic Resource
    Megestrol acetate: Phase II study of a single daily administration in advanced breast cancer (1990)
    Springer
    Breast cancer research and treatment 17 (1990), S. 51-54 
    Details
    ISSN: 1573-7217
    Keywords: endocrine therapy ; megestrol acetate ; progestins
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary A new formulation of megestrol acetate, a semisynthetic oral progestin used in the hormonal treatment of breast cancer, allows the administration of 160 mg of the drug in a single daily dose. Sixty-nine postmenopausal patients with advanced breast cancer have been treated with this regimen: five patients received megestrol acetate as first-line treatment of their metastatic disease, while all the others had been previously treated with one or more regimens of chemotherapy and/or hormone therapy. The median duration of the treatment for evaluable patients was 3 months (range 1–13+). Among 65 evaluable patients 2 complete responses and 12 partial responses (objective response rate 21.5%; 95% confidence limits 12.31%–33.49%) were observed. Median duration of response was 7 months (range 2–12+). Responses were observed both in visceral and in non-visceral sites of disease. Twenty-nine patients obtained a stabilization of disease (44.7%), and twenty-two progressed (33.8%). Median duration of stabilization was 4 months (range 3–13+). Median survival for all patients from the start of megestrol acetate was 9 months (range 1–22+). The most common side effect of therapy was weight gain, occurring in 36% of patients. Megestrol acetate on a single-daily-dose schedule can be considered as an interesting hormonal treatment for advanced breast cancer, especially in the clinical instance of patients who, after having obtained a remission or stabilization of disease with tamoxifen, need further palliative treatment.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01812684
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 5
    Electronic Resource
    Electronic Resource
    Effect of fenretinide on bone mineral density and metabolism in women with early breast cancer (1999)
    Springer
    Breast cancer research and treatment 53 (1999), S. 145-151 
    Details
    ISSN: 1573-7217
    Keywords: breast ; bone mineral density ; neoplasms ; bone remodeling ; chemoprevention ; retinoids
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Prolonged administration of natural or synthetic retinoids has been associated with significant skeletal abnormalities, including osteoporosis. We studied the effects of the synthetic retinoid fenretinide (N-4-hydroxyphenylretinamide, or 4-HPR) administered for a mean of 40 months on bone mineral density and metabolism in 66 consecutive women with early breast cancer belonging to a secondary prevention trial. The mean (±SD) bone mineral density at the distal and ultradistal forearm were, respectively, 0.61±0.08 and 0.30±0.05 g/cm2 in 33 treated women and 0.62±0.07 and 0.29±0.07 g/cm2 in 33 control women (p = ns for both). Also, no significant difference was observed in markers of bone formation such as bone alkaline phosphatase and osteocalcin, nor in urinary bone resorption markers such as calcium, hydroxyproline, and type I bone collagen cross-linked N-telopeptide (NTx). However, a border-line higher excretion of urinary calcium and NTx was found in the 4-HPR group after adjustment for menopausal status. We conclude that prolonged administration of 4-HPR is not associated with significant alterations of bone mineral density of the forearm. However, a trend towards an increase in bone resorption markers suggests the need for further assessment at different skeletal sites.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1023/A:1006160523497
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...